MethylGene Reports Clinical Data From a Phase II Study Evaluating MGCD0103 in Relapsed or Refractory Non-Hodgkin Lymphomas

CHICAGO, ILLINOIS--(Marketwire - June 03, 2008) - MethylGene Inc. (TSX: MYG) today announced preliminary data from a Phase II clinical study evaluating MGCD0103, a novel, isoform-selective histone deacetylase (HDAC) inhibitor, in relapsed or refractory non-Hodgkin lymphomas (Trial 008). Results from this single-agent trial, conducted in collaboration with Celgene Corporation and Taiho Pharmaceutical, were presented today at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
MORE ON THIS TOPIC